Robert K. Stuart

Title
InstitutionMedical University of South Carolina
DepartmentHematology/Oncology
AddressP.O. Box MSC 635
305
86 Jonathan Lucas St.
Phone843-792-4271
Fax843-792-8641
vCardDownload vCard

    Collapse Overview 
    Collapse keywords
    Children-s Health, Drug Studies, Minorities, Pediatrics, Blood Disorders, Cancer/Lymphoma, Men-s Health, Transplant, Cancer, Cancer/Leukemia, Cancer/Myeloma, Cancer/Other, Women-s Health

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Herrera AF, Ahn KW, Litovich C, Chen Y, Assal A, Bashir Q, Bayer RL, Coleman M, DeFilipp Z, Farhadfar N, Greenwood M, Hahn T, Horwitz M, Jacobson C, Jaglowski S, Lachance S, Langston A, Mattar B, Maziarz RT, McGuirk J, Mian MAH, Nathan S, Phillips A, Rakszawski K, Sengeloev H, Shenoy S, Stuart R, Sauter CS, Kharfan-Dabaja MA, Hamadani M, Herrera AF, Ahn KW, Litovich C, Chen Y, Assal A, Bashir Q, Bayer RL, Coleman M, DeFilipp Z, Farhadfar N, Greenwood M, Hahn T, Horwitz M, Jacobson C, Jaglowski S, Lachance S, Langston A, Mattar B, Maziarz RT, McGuirk J, Mian MAH, Nathan S, Phillips A, Rakszawski K, Sengeloev H, Shenoy S, Stuart R, Sauter CS, Kharfan-Dabaja MA, Hamadani M. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. Blood Adv. 2021 09 28; 5(18):3528-3539. PMID: 34496026; PMCID: PMC8945575.
      Citations:    
    2. Walker AR, Marcucci G, Yin J, Blum W, Stock W, Kohlschmidt J, Mrózek K, Carroll AJ, Eisfeld AK, Wang ES, Jacobson S, Kolitz JE, Thakuri M, Sutamtewagul G, Vij R, Stuart RK, Byrd JC, Bloomfield CD, Stone RM, Larson RA, Walker AR, Marcucci G, Yin J, Blum W, Stock W, Kohlschmidt J, Mr?zek K, Carroll AJ, Eisfeld AK, Wang ES, Jacobson S, Kolitz JE, Thakuri M, Sutamtewagul G, Vij R, Stuart RK, Byrd JC, Bloomfield CD, Stone RM, Larson RA. Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Adv. 2021 07 13; 5(13):2775-2787. PMID: 34251414; PMCID: PMC8288671.
      Citations:    
    3. Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S, Cortes JE, Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S, Cortes JE. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021 Jul; 8(7):e481-e491. PMID: 34171279.
      Citations:    
    4. Jillella AP, Arellano ML, Gaddh M, Langston AA, Heffner LT, Winton EF, McLemore ML, Zhang C, Caprara CR, Simon KS, Bolds SL, DeBragga S, Karkhanis P, Krishnamurthy SH, Tongol J, El Geneidy MM, Pati A, Gerber JM, Grunwald MR, Cortes J, Bashey A, Stuart RK, Kota VK, Jillella AP, Arellano ML, Gaddh M, Langston AA, Heffner LT, Winton EF, McLemore ML, Zhang C, Caprara CR, Simon KS, Bolds SL, DeBragga S, Karkhanis P, Krishnamurthy SH, Tongol J, El Geneidy MM, Pati A, Gerber JM, Grunwald MR, Cortes J, Bashey A, Stuart RK, Kota VK. Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia. JCO Oncol Pract. 2021 04; 17(4):e497-e505. PMID: 33125295; PMCID: PMC8202058.
      Citations:    
    5. Chari A, Cornell RF, Gasparetto C, Karanes C, Matous JV, Niesvizky R, Lunning M, Usmani SZ, Anderson LD, Chhabra S, Girnius S, Shustik C, Stuart R, Lee Y, Salman Z, Liu E, Valent J, Chari A, Cornell RF, Gasparetto C, Karanes C, Matous JV, Niesvizky R, Lunning M, Usmani SZ, Anderson LD, Chhabra S, Girnius S, Shustik C, Stuart R, Lee Y, Salman Z, Liu E, Valent J. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematol Oncol. 2020 Aug; 38(3):353-362. PMID: 32053229; PMCID: PMC7496325.
      Citations:    
    6. Kolitz JE, Strickland SA, Cortes JE, Hogge D, Lancet JE, Goldberg SL, Villa KF, Ryan RJ, Chiarella M, Louie AC, Ritchie EK, Stuart RK, Kolitz JE, Strickland SA, Cortes JE, Hogge D, Lancet JE, Goldberg SL, Villa KF, Ryan RJ, Chiarella M, Louie AC, Ritchie EK, Stuart RK. Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. Leuk Lymphoma. 2020 03; 61(3):631-640. PMID: 31760835.
      Citations:    
    7. Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ, Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740. PMID: 31665578.
      Citations:    
    8. DeAngelo DJ, Walker AR, Schlenk RF, Sierra J, Medeiros BC, Ocio EM, Röllig C, Strickland SA, Thol F, Valera SZ, Dasgupta K, Berkowitz N, Stuart RK, DeAngelo DJ, Walker AR, Schlenk RF, Sierra J, Medeiros BC, Ocio EM, R?llig C, Strickland SA, Thol F, Valera SZ, Dasgupta K, Berkowitz N, Stuart RK. Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leuk Res. 2019 10; 85:106197. PMID: 31541945; PMCID: PMC7108400.
      Citations:    
    9. Orr RK, Hoehn JL, Col NF, Hamilton BK, Liu Y, Hemmer MT, Majhail N, Ringden O, Kim D, Costa L, Stuart R, Alousi A, Pidala JA, Couriel DR, Aljurf M, Antin JH, Bredeson C, Cahn JY, Cairo M, Choi SW, Dandoy C, Gale RP, Gergis U, Hematti P, Inamoto Y, Kamble RT, MacMillan M, Marks DI, Nemecek E, Nishihori T, Saad A, Savani BN, Schriber J, Seo S, Soci? G, Teshima T, Verdonck LF, Waller EK, Wirk M, Spellman SR, Arora M, Chhabra S. Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 09; 25(9):1744-1755. PMID: 31158502; PMCID: PMC7039394.
      Citations:    
    10. Lin TL, Newell LF, Stuart RK, Michaelis LC, Rubenstein E, Pentikis HS, Callahan T, Alvarez D, Liboiron BD, Mayer LD, Wang Q, Banerjee K, Louie AC, Lin TL, Newell LF, Stuart RK, Michaelis LC, Rubenstein E, Pentikis HS, Callahan T, Alvarez D, Liboiron BD, Mayer LD, Wang Q, Banerjee K, Louie AC. A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias. Cancer Chemother Pharmacol. 2019 07; 84(1):163-173. PMID: 31098682; PMCID: PMC6562048.
      Citations:    
    11. McGowan DR, Skwarski M, Bradley KM, Campo L, Fenwick JD, Gleeson FV, Green M, Horne A, Maughan TS, McCole MG, Mohammed S, Muschel RJ, Ng SM, Panakis N, Prevo R, Strauss VY, Stuart R, Tacconi EMC, Vallis KA, McKenna WG, Macpherson RE, Higgins GS, McGowan DR, Skwarski M, Bradley KM, Campo L, Fenwick JD, Gleeson FV, Green M, Horne A, Maughan TS, McCole MG, Mohammed S, Muschel RJ, Ng SM, Panakis N, Prevo R, Strauss VY, Stuart R, Tacconi EMC, Vallis KA, McKenna WG, Macpherson RE, Higgins GS. Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma. Eur J Cancer. 2019 05; 113:87-95. PMID: 30991262; PMCID: PMC6522060.
      Citations:    
    12. Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, Atallah E, Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, Atallah E. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv. 2019 02 26; 3(4):508-518. PMID: 30760466; PMCID: PMC6391673.
      Citations:    
    13. Porter M, Shadbolt B, Ye X, Stuart R, Porter M, Shadbolt B, Ye X, Stuart R. Ankle Lateral Ligament Augmentation Versus the Modified Brostr?m-Gould Procedure: A 5-Year Randomized Controlled Trial. Am J Sports Med. 2019 03; 47(3):659-666. PMID: 30699039.
      Citations:    
    14. Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W, Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv. 2018 11 13; 2(21):2922-2936. PMID: 30396912; PMCID: PMC6234373.
      Citations:    
    15. Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK, Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biol Blood Marrow Transplant. 2019 01; 25(1):73-85. PMID: 30153491; PMCID: PMC6355336.
      Citations:    
    16. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC, Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018 09 10; 36(26):2684-2692. PMID: 30024784; PMCID: PMC6127025.
      Citations:    
    17. DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM, DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018 Jun 21; 378(25):2386-2398. PMID: 29860938.
      Citations:    
    18. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK, Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, R?cher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK. Phase 3 results for vosaroxin/cytarabine in the subset of patients =60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 11; 103(11):e514-e518. PMID: 29794146; PMCID: PMC6278965.
      Citations:    
    19. Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, Westervelt P, DiPersio JF, Hillman TM, Silver N, Szarek M, Gorelik L, Lowdell MW, Rowinsky E, Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, Westervelt P, DiPersio JF, Hillman TM, Silver N, Szarek M, Gorelik L, Lowdell MW, Rowinsky E. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2018 08; 24(8):1581-1589. PMID: 29597002; PMCID: PMC6232080.
      Citations:    
    20. Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M, Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, R?llig C, Neubauer A, Martinelli G, Bahceci E, Levis M. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017 08; 18(8):1061-1075. PMID: 28645776; PMCID: PMC5572576.
      Citations:    
    21. Sedov V, Stuart RK, Sedov V, Stuart RK. Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape. Ther Adv Hematol. 2017 Jun; 8(6):185-195. PMID: 28567238; PMCID: PMC5424861.
      Citations:    
    22. Jensen DM, Eklund S, Persson T, Ahlbom H, Stuart R, Barkun AN, Kuipers EJ, Mössner J, Lau JY, Sung JJ, Kilhamn J, Lind T, Jensen DM, Eklund S, Persson T, Ahlbom H, Stuart R, Barkun AN, Kuipers EJ, M?ssner J, Lau JY, Sung JJ, Kilhamn J, Lind T. Reassessment of Rebleeding Risk of Forrest IB (Oozing) Peptic Ulcer Bleeding in a Large International Randomized Trial. Am J Gastroenterol. 2017 03; 112(3):441-446. PMID: 28094314; PMCID: PMC5612665.
      Citations:    
    23. Green MM, Chao N, Chhabra S, Corbet K, Gasparetto C, Horwitz A, Li Z, Venkata JK, Long G, Mims A, Rizzieri D, Sarantopoulos S, Stuart R, Sung AD, Sullivan KM, Costa L, Horwitz M, Kang Y, Green MM, Chao N, Chhabra S, Corbet K, Gasparetto C, Horwitz A, Li Z, Venkata JK, Long G, Mims A, Rizzieri D, Sarantopoulos S, Stuart R, Sung AD, Sullivan KM, Costa L, Horwitz M, Kang Y. Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. J Hematol Oncol. 2016 08 17; 9(1):71. PMID: 27535663; PMCID: PMC4989381.
      Citations:    
    24. Orr RK, Hoehn JL, Col NF, Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036. PMID: 26234174; PMCID: PMC4822512.
      Citations:    
    25. Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B, Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015 Apr 10; 33(11):1252-7. PMID: 25732165.
      Citations:    
    26. Costa LJ, Fanning SR, Stephenson J, Afrin LB, Kistner-Griffin E, Bentz TA, Stuart RK, Costa LJ, Fanning SR, Stephenson J, Afrin LB, Kistner-Griffin E, Bentz TA, Stuart RK. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma. 2015 Mar; 56(3):645-9. PMID: 25130476.
      Citations:    
    27. Fayad L, Ansell SM, Advani R, Coiffier B, Stuart R, Bartlett NL, Forero-Torres A, Kuliczkowski K, Belada D, Ng E, Drachman JG, Fayad L, Ansell SM, Advani R, Coiffier B, Stuart R, Bartlett NL, Forero-Torres A, Kuliczkowski K, Belada D, Ng E, Drachman JG. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leuk Lymphoma. 2015; 56(9):2569-78. PMID: 25651427.
      Citations:    
    28. God JM, Cameron C, Figueroa J, Amria S, Hossain A, Kempkes B, Bornkamm GW, Stuart RK, Blum JS, Haque A, God JM, Cameron C, Figueroa J, Amria S, Hossain A, Kempkes B, Bornkamm GW, Stuart RK, Blum JS, Haque A. Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors. J Immunol. 2015 Feb 15; 194(4):1434-45. PMID: 25595783; PMCID: PMC4323931.
      Citations:    
    29. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL, Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 26; 125(9):1367-76. PMID: 25550361; PMCID: PMC4342352.
      Citations:    
    30. Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F, Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2015 Mar; 168(6):796-805. PMID: 25403830; PMCID: PMC4354261.
      Citations:    
    31. Lancet JE, Roboz GJ, Cripe LD, Michelson GC, Fox JA, Leavitt RD, Chen T, Hawtin R, Craig AR, Ravandi F, Maris MB, Stuart RK, Karp JE, Lancet JE, Roboz GJ, Cripe LD, Michelson GC, Fox JA, Leavitt RD, Chen T, Hawtin R, Craig AR, Ravandi F, Maris MB, Stuart RK, Karp JE. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica. 2015 Feb; 100(2):231-7. PMID: 25381131; PMCID: PMC4803139.
      Citations:    
    32. Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S, Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res. 2014 Nov 15; 20(22):5652-62. PMID: 25248382; PMCID: PMC4233160.
      Citations:    
    33. Venkata JK, An N, Stuart R, Costa LJ, Cai H, Coker W, Song JH, Gibbs K, Matson T, Garrett-Mayer E, Wan Z, Ogretmen B, Smith C, Kang Y, Venkata JK, An N, Stuart R, Costa LJ, Cai H, Coker W, Song JH, Gibbs K, Matson T, Garrett-Mayer E, Wan Z, Ogretmen B, Smith C, Kang Y. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood. 2014 Sep 18; 124(12):1915-25. PMID: 25122609; PMCID: PMC4168346.
      Citations:    
    34. Porter M, Shadbolt B, Stuart R, Porter M, Shadbolt B, Stuart R. Primary ankle ligament augmentation versus modified Brostrom-Gould procedure: a 2-year randomized controlled trial. ANZ J Surg. 2015 Jan; 85(1-2):44-8. PMID: 25171115.
      Citations:    
    35. Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, Shanley R, Hogan WJ, Perales MA, Shore T, Baurmann H, Stuart R, Gruhn B, Doubek M, Hsu JW, Tholouli E, Gromke T, Godley LA, Pagano L, Gilman A, Wagner EM, Shwayder T, Bornhäuser M, Papadopoulos EB, Böhm A, Vercellotti G, Van Lint MT, Schmid C, Rabitsch W, Pullarkat V, Legrand F, Yakoub-Agha I, Saber W, Barrett J, Hermine O, Hagglund H, Sperr WR, Popat U, Alyea EP, Devine S, Deeg HJ, Weisdorf D, Akin C, Valent P, Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, Shanley R, Hogan WJ, Perales MA, Shore T, Baurmann H, Stuart R, Gruhn B, Doubek M, Hsu JW, Tholouli E, Gromke T, Godley LA, Pagano L, Gilman A, Wagner EM, Shwayder T, Bornh?user M, Papadopoulos EB, B?hm A, Vercellotti G, Van Lint MT, Schmid C, Rabitsch W, Pullarkat V, Legrand F, Yakoub-Agha I, Saber W, Barrett J, Hermine O, Hagglund H, Sperr WR, Popat U, Alyea EP, Devine S, Deeg HJ, Weisdorf D, Akin C, Valent P. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014 Oct 10; 32(29):3264-74. PMID: 25154823; PMCID: PMC4876356.
      Citations:    
    36. Schade H, Chhabra S, Kang Y, Stuart RK, Edwards KH, Kramer C, Butcher C, Littleton A, Schneider M, Budisavljevic MN, Costa LJ, Schade H, Chhabra S, Kang Y, Stuart RK, Edwards KH, Kramer C, Butcher C, Littleton A, Schneider M, Budisavljevic MN, Costa LJ. Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor. Transfusion. 2014 Dec; 54(12):3131-7. PMID: 24947954.
      Citations:    
    37. Costa LJ, Nista EJ, Buadi FK, Lacy MQ, Dispenzieri A, Kramer CP, Edwards KH, Kang Y, Gertz MA, Stuart RK, Kumar S, Costa LJ, Nista EJ, Buadi FK, Lacy MQ, Dispenzieri A, Kramer CP, Edwards KH, Kang Y, Gertz MA, Stuart RK, Kumar S. Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification. Biol Blood Marrow Transplant. 2014 Feb; 20(2):222-8. PMID: 24211319.
      Citations:    
    38. Mims A, Stuart RK, Mims A, Stuart RK. Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there? Curr Hematol Malig Rep. 2013 Jun; 8(2):156-62. PMID: 23640069.
      Citations:    
    39. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, Larson RA, Erba HP, Stiff PJ, Stuart RK, Walter RB, Tallman MS, Stenke L, Appelbaum FR, Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, Larson RA, Erba HP, Stiff PJ, Stuart RK, Walter RB, Tallman MS, Stenke L, Appelbaum FR. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013 Jun 13; 121(24):4854-60. PMID: 23591789; PMCID: PMC3682338.
      Citations:    
    40. Costa LJ, Abbas J, Ortiz-Cruz KL, Kang Y, Stuart RK, Costa LJ, Abbas J, Ortiz-Cruz KL, Kang Y, Stuart RK. Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange. Eur J Haematol. 2012 Nov; 89(5):432-4. PMID: 22971164.
      Citations:    
    41. Abbas JA, Stuart RK, Abbas JA, Stuart RK. Vosaroxin : a novel antineoplastic quinolone. Expert Opin Investig Drugs. 2012 Aug; 21(8):1223-33. PMID: 22724917.
      Citations:    
    42. Butler C, Wolff DJ, Kang Y, Stuart RK, Costa LJ, Butler C, Wolff DJ, Kang Y, Stuart RK, Costa LJ. Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients. Leuk Lymphoma. 2012 Dec; 53(12):2444-8. PMID: 22574971.
      Citations:    
    43. Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM, Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012 Jul 10; 30(20):2492-9. PMID: 22585697; PMCID: PMC4874149.
      Citations:    
    44. Costa LJ, Abbas J, Hogan KR, Kramer C, McDonald K, Butcher CD, Littleton A, Shoptaw K, Kang Y, Stuart RK, Costa LJ, Abbas J, Hogan KR, Kramer C, McDonald K, Butcher CD, Littleton A, Shoptaw K, Kang Y, Stuart RK. Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant. 2012 Nov; 47(11):1403-8. PMID: 22484324.
      Citations:    
    45. Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, Kang Y, Stuart RK, Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, Kang Y, Stuart RK. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. 2012 Nov; 52(11):2375-81. PMID: 22404694.
      Citations:    
    46. Rivell GL, Brunson CY, Milligan L, Stuart RK, Costa LJ, Rivell GL, Brunson CY, Milligan L, Stuart RK, Costa LJ. Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents. Am J Hematol. 2011 Aug; 86(8):699-701. PMID: 21630309.
      Citations:    
    47. Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR, Obeid LM, El-Shewy HM, Oaks J, Santhanam R, Marcucci G, Baran Y, Mahajan S, Fernandes D, Stuart R, Perrotti D, Ogretmen B, Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR, Obeid LM, El-Shewy HM, Oaks J, Santhanam R, Marcucci G, Baran Y, Mahajan S, Fernandes D, Stuart R, Perrotti D, Ogretmen B. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood. 2011 Jun 02; 117(22):5941-52. PMID: 21527515; PMCID: PMC3112039.
      Citations:    
    48. Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD, Kolla S, Doyle A, Wright J, Sullivan DM, Roberts JD, Grant S, Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD, Kolla S, Doyle A, Wright J, Sullivan DM, Roberts JD, Grant S. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res. 2011 May 15; 17(10):3388-97. PMID: 21447728; PMCID: PMC3096752.
      Citations:    
    49. Alexander ET, Towery JA, Miller AN, Kramer C, Hogan KR, Squires JE, Stuart RK, Costa LJ, Alexander ET, Towery JA, Miller AN, Kramer C, Hogan KR, Squires JE, Stuart RK, Costa LJ. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Transfusion. 2011 Sep; 51(9):1995-2000. PMID: 21392017.
      Citations:    
    50. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Wiktor-Jedrzejczak W, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD, Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Wiktor-Jedrzejczak W, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011 Mar 24; 117(12):3294-301. PMID: 21270442; PMCID: PMC3069671.
      Citations:    
    51. Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, Cubitt C, Blaskovich MA, Wright JJ, Sebti S, Sullivan DM, Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, Cubitt C, Blaskovich MA, Wright JJ, Sebti S, Sullivan DM. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res. 2011 Mar 01; 17(5):1140-6. PMID: 21233404; PMCID: PMC3049960.
      Citations:    
    52. Miller AN, Glode A, Hogan KR, Schaub C, Kramer C, Stuart RK, Costa LJ, Miller AN, Glode A, Hogan KR, Schaub C, Kramer C, Stuart RK, Costa LJ. Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011 Aug; 17(8):1176-81. PMID: 21185389.
      Citations:    
    53. Kuipers EJ, Sung JJ, Barkun A, Mössner J, Jensen D, Stuart R, Lau JY, Ahlbom H, Lind T, Kilhamn J, Kuipers EJ, Sung JJ, Barkun A, M?ssner J, Jensen D, Stuart R, Lau JY, Ahlbom H, Lind T, Kilhamn J. Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding. Adv Ther. 2011 Feb; 28(2):150-9. PMID: 21181319.
      Citations:    
    54. Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP, Stiff PJ, Appelbaum FR, Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP, Stiff PJ, Appelbaum FR. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol. 2010 Dec; 151(5):430-4. PMID: 21113977; PMCID: PMC3058291.
      Citations:    
    55. Adams B, Lazarchick J, Medina AM, Willner IR, Neville B, Murphy E, Stuart R, Costa LJ, Adams B, Lazarchick J, Medina AM, Willner IR, Neville B, Murphy E, Stuart R, Costa LJ. Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. Am J Hematol. 2010 Aug; 85(8):627-9. PMID: 20658594.
      Citations:    
    56. Toms DR, Cannick L, Stuart RK, Jenrette JM, Terwiliger L, Toms DR, Cannick L, Stuart RK, Jenrette JM, Terwiliger L. Helical tomotherapy for extramedullary hematopoiesis involving the pericardium in a patient with chronic myeloid leukemia. Jpn J Radiol. 2010 Jul; 28(6):476-8. PMID: 20661700.
      Citations:    
    57. Costa LJ, Moussa O, Bray RA, Stuart RK, Costa LJ, Moussa O, Bray RA, Stuart RK. Overcoming HLA-DPB1 donor specific antibody-mediated haematopoietic graft failure. Br J Haematol. 2010 Oct; 151(1):94-6. PMID: 20636435.
      Citations:    
    58. Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C, Stuart RK, Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C, Stuart RK. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant. 2011 Apr; 46(4):523-8. PMID: 20622909.
      Citations:    
    59. Post GR, Holloman D, Christiansen L, Smith J, Stuart R, Lazarchick J, Post GR, Holloman D, Christiansen L, Smith J, Stuart R, Lazarchick J. Translocation t(3;8;9)(p25;p21;q34) in a patient with features of 8p11 myeloproliferative syndrome: a unique case and review of the literature. Leuk Res. 2010 Nov; 34(11):1543-4. PMID: 20541805.
      Citations:    
    60. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK, Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant. 2011 Jan; 46(1):64-9. PMID: 20383210.
      Citations:    
    61. Shabbir M, Stuart R, Shabbir M, Stuart R. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin Investig Drugs. 2010 Mar; 19(3):427-36. PMID: 20141349.
      Citations:    
    62. Matmati K, Matmati N, Hannun YA, Rumboldt Z, Patel S, Lazarchick J, Stuart R, Giglio P, Matmati K, Matmati N, Hannun YA, Rumboldt Z, Patel S, Lazarchick J, Stuart R, Giglio P. Dural MALT lymphoma with disseminated disease. Hematol Rep. 2010 Jan 26; 2(1):e10. PMID: 22184513; PMCID: PMC3222263.
      Citations:    
    63. Barkun AN, Adam V, Sung JJ, Kuipers EJ, Mössner J, Jensen D, Stuart R, Lau JY, Nauclér E, Kilhamn J, Granstedt H, Liljas B, Lind T, Barkun AN, Adam V, Sung JJ, Kuipers EJ, M?ssner J, Jensen D, Stuart R, Lau JY, Naucl?r E, Kilhamn J, Granstedt H, Liljas B, Lind T. Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding. Pharmacoeconomics. 2010; 28(3):217-30. PMID: 20151726.
      Citations:    
    64. Orr RK, Hoehn JL, Col NF, Schiller GJ, O'Brien SM, Pigneux A, Deangelo DJ, Vey N, Kell J, Solomon S, Stuart RK, Karsten V, Cahill AL, Albitar MX, Giles FJ. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J Clin Oncol. 2010 Feb 10; 28(5):815-21. PMID: 20026800.
      Citations:    
    65. Holloman D, Eberts P, Clark C, Lewin D, Lazarchick J, Stuart R, Comerford L, Holloman D, Eberts P, Clark C, Lewin D, Lazarchick J, Stuart R, Comerford L. Extensive involvement of the gastrointestinal tract by a de novo presentation of the monoblastic type of myeloid sarcoma: a case report of a rare entity that is often misdiagnosed. Am J Med Sci. 2009 Dec; 338(6):513-6. PMID: 20010158.
      Citations:    
    66. Shirai K, Sera Y, Bulkeley W, Mehrotra M, Moussa O, LaRue AC, Watson DK, Stuart RK, Lazarchick J, Ogawa M, Shirai K, Sera Y, Bulkeley W, Mehrotra M, Moussa O, LaRue AC, Watson DK, Stuart RK, Lazarchick J, Ogawa M. Hematopoietic stem cell origin of human fibroblasts: cell culture studies of female recipients of gender-mismatched stem cell transplantation and patients with chronic myelogenous leukemia. Exp Hematol. 2009 Dec; 37(12):1464-71. PMID: 19786066; PMCID: PMC2802494.
      Citations:    
    67. Giles F, Vey N, DeAngelo D, Seiter K, Stock W, Stuart R, Boskovic D, Pigneux A, Tallman M, Brandwein J, Kell J, Robak T, Staib P, Thomas X, Cahill A, Albitar M, O'Brien S, Giles F, Vey N, DeAngelo D, Seiter K, Stock W, Stuart R, Boskovic D, Pigneux A, Tallman M, Brandwein J, Kell J, Robak T, Staib P, Thomas X, Cahill A, Albitar M, O'Brien S. Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood. 2009 Nov 05; 114(19):4027-33. PMID: 19710500.
      Citations:    
    68. Gattoni-Celli S, Buckner CL, Lazarchick J, Stuart RK, Fernandes DJ, Gattoni-Celli S, Buckner CL, Lazarchick J, Stuart RK, Fernandes DJ. Overexpression of nucleolin in engrafted acute myelogenous leukemia cells. Am J Hematol. 2009 Aug; 84(8):535-8. PMID: 19554553.
      Citations:    
    69. Watkins JM, Shirai KS, Wahlquist AE, Stuart RK, Chaudhary UB, Garrett-Mayer E, Day TA, Gillespie MB, Sharma AK, Watkins JM, Shirai KS, Wahlquist AE, Stuart RK, Chaudhary UB, Garrett-Mayer E, Day TA, Gillespie MB, Sharma AK. Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck. 2009 Apr; 31(4):493-502. PMID: 19156831.
      Citations:    
    70. Sung JJ, Barkun A, Kuipers EJ, Mössner J, Jensen DM, Stuart R, Lau JY, Ahlbom H, Kilhamn J, Lind T, Sung JJ, Barkun A, Kuipers EJ, M?ssner J, Jensen DM, Stuart R, Lau JY, Ahlbom H, Kilhamn J, Lind T, Peptic Ulcer Bleed Study Group. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2009 Apr 07; 150(7):455-64. PMID: 19221370.
      Citations:    
    71. Orr RK, Hoehn JL, Col NF, Vu KN, Day TA, Gillespie MB, Martin-Harris B, Sinha D, Stuart RK, Sharma AK. Proximal esophageal stenosis in head and neck cancer patients after total laryngectomy and radiation. ORL J Otorhinolaryngol Relat Spec. 2008; 70(4):229-35. PMID: 18467817; PMCID: PMC7670489.
      Citations:    
    72. Znoyko I, Stuart RK, Ellingham T, Winters J, Wolff DJ, Quigley DI, Znoyko I, Stuart RK, Ellingham T, Winters J, Wolff DJ, Quigley DI. Tetraploidy and 5q deletion in myelodysplastic syndrome: a case report. Cancer Genet Cytogenet. 2008 May; 183(1):64-8. PMID: 18474300.
      Citations:    
    73. Amria S, Cameron C, Stuart R, Haque A, Amria S, Cameron C, Stuart R, Haque A. Defects in HLA class II antigen presentation in B-cell lymphomas. Leuk Lymphoma. 2008 Feb; 49(2):353-5. PMID: 18231926.
      Citations:    
    74. Watkins JM, Stuart RK, Davis BK, Day TA, Chaudharry UB, Sharma AK, Watkins JM, Stuart RK, Davis BK, Day TA, Chaudharry UB, Sharma AK. Long-term survival following salvage reirradiation with concurrent chemotherapy for recurrent head and neck cancer. J S C Med Assoc. 2008 Feb; 104(2):36-9. PMID: 18396601.
      Citations:    
    75. Sung JJ, Mössner J, Barkun A, Kuipers EJ, Lau J, Jensen D, Stuart R, Junghard O, Olsson G, Sung JJ, M?ssner J, Barkun A, Kuipers EJ, Lau J, Jensen D, Stuart R, Junghard O, Olsson G, Pub Study Group. Intravenous esomeprazole for prevention of peptic ulcer re-bleeding: rationale/design of Peptic Ulcer Bleed study. Aliment Pharmacol Ther. 2008 Apr; 27(8):666-77. PMID: 18248654.
      Citations:    
    76. Koch DG, Christiansen L, Lazarchick J, Stuart R, Willner IR, Reuben A, Koch DG, Christiansen L, Lazarchick J, Stuart R, Willner IR, Reuben A. Posttransplantation lymphoproliferative disorder--the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus. Liver Transpl. 2007 Jun; 13(6):904-12. PMID: 17539010.
      Citations:    
    77. Otake Y, Soundararajan S, Sengupta TK, Kio EA, Smith JC, Pineda-Roman M, Stuart RK, Spicer EK, Fernandes DJ, Otake Y, Soundararajan S, Sengupta TK, Kio EA, Smith JC, Pineda-Roman M, Stuart RK, Spicer EK, Fernandes DJ. Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. Blood. 2007 Apr 01; 109(7):3069-75. PMID: 17179226; PMCID: PMC1852223.
      Citations:    
    78. Bilic M, Quigley DI, Stuart RK, Wolff DJ, Bilic M, Quigley DI, Stuart RK, Wolff DJ. Jumping translocation of 1q in BCR/ABL-positive acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2007 Jan 01; 172(1):90-1. PMID: 17175389.
      Citations:    
    79. Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, Moore J, Koller M, Turhal NS, Stuart R, Van Cutsem E, D'haese S, Coens C, Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, Moore J, Koller M, Turhal NS, Stuart R, Van Cutsem E, D'haese S, Coens C, European Organisation for Research and Treatment of Cancer Gastrointestinal and Quality of Life Grou. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer. 2004 Oct; 40(15):2260-8. PMID: 15454251.
      Citations:    
    80. Day TA, Deveikis J, Gillespie MB, Joe JK, Ogretmen B, Osguthorpe JD, Reed SG, Richardson MS, Rossi M, Saini R, Sharma AK, Stuart RK, Day TA, Deveikis J, Gillespie MB, Joe JK, Ogretmen B, Osguthorpe JD, Reed SG, Richardson MS, Rossi M, Saini R, Sharma AK, Stuart RK. Salivary gland neoplasms. Curr Treat Options Oncol. 2004 Feb; 5(1):11-26. PMID: 14697153.
      Citations: 9     Fields:    Translation:Humans
    81. Onitilo AA, Lazarchick J, Brunson CY, Frei-Lahr D, Stuart RK, Onitilo AA, Lazarchick J, Brunson CY, Frei-Lahr D, Stuart RK. Autologous bone marrow transplant in a patient with sickle cell disease and diffuse large B-cell lymphoma. Transplant Proc. 2003 Dec; 35(8):3089-92. PMID: 14697986.
      Citations: 3     Fields:    Translation:Humans
    82. Day TA, Davis BK, Gillespie MB, Joe JK, Kibbey M, Martin-Harris B, Neville B, Reed SG, Richardson MS, Rosenzweig S, Sharma AK, Smith MM, Stewart S, Stuart RK, Day TA, Davis BK, Gillespie MB, Joe JK, Kibbey M, Martin-Harris B, Neville B, Reed SG, Richardson MS, Rosenzweig S, Sharma AK, Smith MM, Stewart S, Stuart RK. Oral cancer treatment. Curr Treat Options Oncol. 2003 02; 4(1):27-41. PMID: 12525277.
      Citations: 28     Fields:    Translation:Humans
    83. Ezzat AA, Ibrahim EM, Ajarim DS, Rahal MM, Raja MA, Stuart RK, Tulbah AM, Kandil A, Al-Malik OA, Bazarbashi SM, Ezzat AA, Ibrahim EM, Ajarim DS, Rahal MM, Raja MA, Stuart RK, Tulbah AM, Kandil A, Al-Malik OA, Bazarbashi SM. High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin. Breast Cancer Res Treat. 2000 Aug; 62(3):237-44. PMID: 11072788.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    84. Gyger M, Stuart RK, Perreault C, Gyger M, Stuart RK, Perreault C. Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor. Bone Marrow Transplant. 2000 Jul; 26(1):1-16. PMID: 10918400.
      Citations: 8     Fields:    Translation:HumansCells
    85. Ezzat AA, Ibrahim EM, Stuart RK, Ajarim D, Bazarbashi S, El-Foudeh MO, Rahal M, Al-Sayed A, Berry J, Ezzat AA, Ibrahim EM, Stuart RK, Ajarim D, Bazarbashi S, El-Foudeh MO, Rahal M, Al-Sayed A, Berry J. Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial. Med Oncol. 2000 Feb; 17(1):39-46. PMID: 10713659.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    86. Harris JE, Ryan L, Hoover HC, Stuart RK, Oken MM, Benson AB, Mansour E, Haller DG, Manola J, Hanna MG, Harris JE, Ryan L, Hoover HC, Stuart RK, Oken MM, Benson AB, Mansour E, Haller DG, Manola J, Hanna MG. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol. 2000 Jan; 18(1):148-57. PMID: 10623705.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    87. Wang HE, O'Connor RE, Megargel RE, Bitner M, Stuart R, Bratton-Heck B, Lamborn M, Tan L, Wang HE, O'Connor RE, Megargel RE, Bitner M, Stuart R, Bratton-Heck B, Lamborn M, Tan L. The utilization of midazolam as a pharmacologic adjunct to endotracheal intubation by paramedics. Prehosp Emerg Care. 2000 Jan-Mar; 4(1):14-8. PMID: 10634276.
      Citations: 2     Fields:    Translation:Humans
    88. Ibrahim EM, Ezzat AA, Raja MA, Rahal MM, Ajarim DS, Mann B, Baloush A, Stuart RK, Bazarbashi SN, Ibrahim EM, Ezzat AA, Raja MA, Rahal MM, Ajarim DS, Mann B, Baloush A, Stuart RK, Bazarbashi SN. Primary gastric non-Hodgkin's lymphoma: clinical features, management, and prognosis of 185 patients with diffuse large B-cell lymphoma. Ann Oncol. 1999 Dec; 10(12):1441-9. PMID: 10643534.
      Citations: 2     Fields:    Translation:Humans
    89. Ezzat AA, Ibrahim EM, Raja MA, Al-Sobhi S, Rostom A, Stuart RK, Ezzat AA, Ibrahim EM, Raja MA, Al-Sobhi S, Rostom A, Stuart RK. Locally advanced breast cancer in Saudi Arabia: high frequency of stage III in a young population. Med Oncol. 1999 Jul; 16(2):95-103. PMID: 10456657.
      Citations: 33     Fields:    Translation:Humans
    90. Bhalla KN, Kumar GN, Walle UK, Ibrado AM, Javed T, Stuart RK, Reed C, Arbuck SG, Walle T, Bhalla KN, Kumar GN, Walle UK, Ibrado AM, Javed T, Stuart RK, Reed C, Arbuck SG, Walle T. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res. 1999 Jul; 5(7):1723-30. PMID: 10430075.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    91. Ezzat A, Raja M, Bakri Y, Subhi J, Memon M, Schwartz P, Stuart R, Ezzat A, Raja M, Bakri Y, Subhi J, Memon M, Schwartz P, Stuart R. Malignant ovarian germ cell tumours -- a survival and prognostic analysis. Acta Oncol. 1999; 38(4):455-60. PMID: 10418712.
      Citations: 2     Fields:    Translation:Humans
    92. Ibrahim EM, al-Mulhim FA, al-Amri A, al-Muhanna FA, Ezzat AA, Stuart RK, Ajarim D, Ibrahim EM, al-Mulhim FA, al-Amri A, al-Muhanna FA, Ezzat AA, Stuart RK, Ajarim D. Breast cancer in the eastern province of Saudi Arabia. Med Oncol. 1998 Dec; 15(4):241-7. PMID: 9951687.
      Citations: 14     Fields:    Translation:Humans
    93. Rogers RL, Javed TA, Ross RE, Virella G, Stuart RK, Frei-Lahr D, Rogers RL, Javed TA, Ross RE, Virella G, Stuart RK, Frei-Lahr D. Transfusion management of an IgA deficient patient with anti-IgA and incidental correction of IgA deficiency after allogeneic bone marrow transplantation. Am J Hematol. 1998 Apr; 57(4):326-30. PMID: 9544978.
      Citations: 3     Fields:    Translation:Humans
    94. Afrin LB, Kuppuswamy V, Slater B, Stuart RK, Afrin LB, Kuppuswamy V, Slater B, Stuart RK. Electronic clinical trial protocol distribution via the World-Wide Web: a prototype for reducing costs and errors, improving accrual, and saving trees. J Am Med Inform Assoc. 1997 Jan-Feb; 4(1):25-35. PMID: 8988471; PMCID: PMC61195.
      Citations: 6     Fields:    Translation:Humans
    95. Hall PD, Benko H, Hogan KR, Stuart RK, Hall PD, Benko H, Hogan KR, Stuart RK. The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol. 1995 Nov; 23(12):1256-60. PMID: 7589279.
      Citations: 8     Fields:    Translation:Humans
    96. Schmitz JC, Stuart RK, Priest DG, Schmitz JC, Stuart RK, Priest DG. Disposition of folic acid and its metabolites: a comparison with leucovorin. Clin Pharmacol Ther. 1994 May; 55(5):501-8. PMID: 8181194.
      Citations: 4     Fields:    Translation:Humans
    97. Afrin LB, Stuart RK, Afrin LB, Stuart RK. Medical therapy of prostate cancer. J S C Med Assoc. 1994 May; 90(5):231-6. PMID: 8028295.
      Citations: 1     Fields:    Translation:Humans
    98. Stuart RK, Stuart RK. Autologous bone marrow transplantation for leukemia. Semin Oncol. 1993 Oct; 20(5 Suppl 6):40-54. PMID: 8211215.
      Citations: 1     Fields:    Translation:HumansAnimals
    99. Bhalla K, Ross R, Jeter E, Madyastha P, Stuart R, Bhalla K, Ross R, Jeter E, Madyastha P, Stuart R. G-CSF improves granulocytopenia in Felty's syndrome without flare-up of arthritis. Am J Hematol. 1993 Feb; 42(2):230-1. PMID: 7679881.
      Citations: 1     Fields:    Translation:Humans
    100. Stuart RK, Baxter JK, Shikora SA, Akerman P, Apovian C, Champagne C, Jennings A, Bistrian BR, Stuart RK, Baxter JK, Shikora SA, Akerman P, Apovian C, Champagne C, Jennings A, Bistrian BR. Reducing arrhythmias associated with central venous catheter insertion or exchange. Nutrition. 1992 Jan-Feb; 8(1):19-21. PMID: 1562783.
      Citations: 1     Fields:    Translation:Humans
    101. Ross RE, Jeter EK, Stuart RK, Self SE, Lavia MF, Ross RE, Jeter EK, Stuart RK, Self SE, Lavia MF. CD34+ and CD33+ stem cells: predictors of hematologic recovery? Prog Clin Biol Res. 1992; 377:505-12. PMID: 1279718.
      Citations:    Fields:    Translation:HumansCells
    102. Priest DG, Schmitz JC, Bunni MA, Stuart RK, Priest DG, Schmitz JC, Bunni MA, Stuart RK. Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst. 1991 Dec 18; 83(24):1806-12. PMID: 1744924.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    103. Sahovic EA, Flick J, Graham CD, Stuart RK, Sahovic EA, Flick J, Graham CD, Stuart RK. Case report: isoimmune inhibition of erythropoiesis following ABO-incompatible bone marrow transplantation. Am J Med Sci. 1991 Dec; 302(6):369-73. PMID: 1772122.
      Citations: 5     Fields:    Translation:HumansCells
    104. Peters RH, Jollow DJ, Stuart RK, Peters RH, Jollow DJ, Stuart RK. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines. Cancer Res. 1991 May 15; 51(10):2536-41. PMID: 2021933.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    105. Stuart RK, Apovian C, Bell SJ, Blackburn GL, Stuart RK, Apovian C, Bell SJ, Blackburn GL. Perioperative nutrition in cancer patients. Nutrition. 1990 Jul-Aug; 6(4 Suppl):4S-6S. PMID: 2152001.
      Citations:    Fields:    Translation:Humans
    106. White DR, Powell BL, Craig JB, Stuart RK, Schnell FM, Goldklang GA, Atkins JN, Jackson DV, Richards F, Muss HB, White DR, Powell BL, Craig JB, Stuart RK, Schnell FM, Goldklang GA, Atkins JN, Jackson DV, Richards F, Muss HB, et al. A phase II trial of high-dose cytarabine and cisplatin in previously untreated non-small cell carcinoma of the lung. A Piedmont Oncology Association Study. Cancer. 1990 Apr 15; 65(8):1700-3. PMID: 2156598.
      Citations:    Fields:    Translation:Humans
    107. Stuart RK, Shikora SA, Akerman P, Lowell JA, Baxter JK, Apovian C, Champagne C, Jennings A, Keane-Ellison M, Bistrian BR, Stuart RK, Shikora SA, Akerman P, Lowell JA, Baxter JK, Apovian C, Champagne C, Jennings A, Keane-Ellison M, Bistrian BR. Incidence of arrhythmia with central venous catheter insertion and exchange. JPEN J Parenter Enteral Nutr. 1990 Mar-Apr; 14(2):152-5. PMID: 2112623.
      Citations: 15     Fields:    Translation:Humans
    108. Peters RH, Stuart RK, Peters RH, Stuart RK. Synergism between 4-hydroperoxycyclophosphamide and cisplatin: importance of incubation sequence and measurement of cisplatin accumulation. Biochem Pharmacol. 1990 Feb 01; 39(3):607-9. PMID: 2306271.
      Citations:    Fields:    Translation:HumansCells
    109. Peters RH, Ballard K, Oatis JE, Jollow DJ, Stuart RK, Peters RH, Ballard K, Oatis JE, Jollow DJ, Stuart RK. Cellular glutathione as a protective agent against 4-hydroperoxycyclophosphamide cytotoxicity in K-562 cells. Cancer Chemother Pharmacol. 1990; 26(6):397-402. PMID: 2225310.
      Citations: 1     Fields:    Translation:HumansCells
    110. Peters RH, Brandon CS, Avila LA, Gale GR, Stuart RK, Peters RH, Brandon CS, Avila LA, Gale GR, Stuart RK. Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update. Prog Clin Biol Res. 1990; 333:57-68. PMID: 2309001.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    111. Carlson LS, Stuart R, Osguthorpe JD, Carlson LS, Stuart R, Osguthorpe JD. Multimodality treatment of advanced head and neck carcinoma. J S C Med Assoc. 1989 Sep; 85(9):409-11. PMID: 2796295.
      Citations:    Fields:    Translation:Humans
    112. Bunni MA, Rembiesa BM, Priest DG, Sahovic E, Stuart R, Bunni MA, Rembiesa BM, Priest DG, Sahovic E, Stuart R. Accumulation of tetrahydrofolates in human plasma after leucovorin administration. Cancer Chemother Pharmacol. 1989; 23(6):353-7. PMID: 2785439.
      Citations: 3     Fields:    Translation:HumansCells
    113. Peters RH, Brandon CS, Avila LA, Colvin OM, Stuart RK, Peters RH, Brandon CS, Avila LA, Colvin OM, Stuart RK. In vitro synergism of 4-hydroperoxycyclophosphamide and cisplatin: relevance for bone marrow purging. Cancer Chemother Pharmacol. 1989; 23(3):129-34. PMID: 2924369.
      Citations: 2     Fields:    Translation:HumansCells
    114. Spivak JL, Hogans BB, Stuart RK, Spivak JL, Hogans BB, Stuart RK. Tumor-promoting phorbol esters support the in vitro proliferation of murine pluripotent hematopoietic stem cells. J Clin Invest. 1989 Jan; 83(1):100-7. PMID: 2463264; PMCID: PMC303649.
      Citations: 1     Fields:    Translation:AnimalsCells
    115. Garvin AJ, Self S, Sahovic EA, Stuart RK, Marchalonis JJ, Garvin AJ, Self S, Sahovic EA, Stuart RK, Marchalonis JJ. The occurrence of a peripheral T-cell lymphoma in a chronically immunosuppressed renal transplant patient. Am J Surg Pathol. 1988 Jan; 12(1):64-70. PMID: 3276237.
      Citations: 1     Fields:    Translation:HumansCells
    116. Szeluga DJ, Stuart RK, Brookmeyer R, Utermohlen V, Santos GW, Szeluga DJ, Stuart RK, Brookmeyer R, Utermohlen V, Santos GW. Nutritional support of bone marrow transplant recipients: a prospective, randomized clinical trial comparing total parenteral nutrition to an enteral feeding program. Cancer Res. 1987 Jun 15; 47(12):3309-16. PMID: 3107808.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    117. Sieber F, Stuart RK, Rowley SD, Sharkis SJ, Sensenbrenner LL, Sieber F, Stuart RK, Rowley SD, Sharkis SJ, Sensenbrenner LL. Dye-mediated photolysis of normal and neoplastic hematopoietic cells. Leuk Res. 1987; 11(1):43-9. PMID: 3807420.
      Citations: 5     Fields:    Translation:HumansCells
    118. Strauss LC, Rowley SD, La Russa VF, Sharkis SJ, Stuart RK, Civin CI, Strauss LC, Rowley SD, La Russa VF, Sharkis SJ, Stuart RK, Civin CI. Antigenic analysis of hematopoiesis. V. Characterization of My-10 antigen expression by normal lymphohematopoietic progenitor cells. Exp Hematol. 1986 Oct; 14(9):878-86. PMID: 3758237.
      Citations: 15     Fields:    Translation:Cells
    119. Yeager AM, Kaizer H, Santos GW, Saral R, Colvin OM, Stuart RK, Braine HG, Burke PJ, Ambinder RF, Burns WH, Yeager AM, Kaizer H, Santos GW, Saral R, Colvin OM, Stuart RK, Braine HG, Burke PJ, Ambinder RF, Burns WH, et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med. 1986 Jul 17; 315(3):141-7. PMID: 3523241.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    120. Stuart RK, Mangan KF, Stuart RK, Mangan KF. Hematologic and cytogenetic remission of 5q-refractory anemia after syngeneic bone marrow transplantation. Am J Med. 1986 Mar; 80(3):503-7. PMID: 3082200.
      Citations: 2     Fields:    Translation:Humans
    121. Kaizer H, Stuart RK, Brookmeyer R, Beschorner WE, Braine HG, Burns WH, Fuller DJ, Korbling M, Mangan KF, Saral R, Kaizer H, Stuart RK, Brookmeyer R, Beschorner WE, Braine HG, Burns WH, Fuller DJ, Korbling M, Mangan KF, Saral R, et al. Autologous bone marrow transplantation in acute leukemia: a phase I study of in vitro treatment of marrow with 4-hydroperoxycyclophosphamide to purge tumor cells. Blood. 1985 Jun; 65(6):1504-10. PMID: 3888315.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    122. Rowley SD, Colvin OM, Stuart RK, Rowley SD, Colvin OM, Stuart RK. Human multilineage progenitor cell sensitivity to 4-hydroperoxycyclophosphamide. Exp Hematol. 1985 May; 13(4):295-8. PMID: 3987832.
      Citations: 1     Fields:    Translation:HumansCells
    123. Szeluga DJ, Stuart RK, Brookmeyer R, Utermohlen V, Santos GW, Szeluga DJ, Stuart RK, Brookmeyer R, Utermohlen V, Santos GW. Energy requirements of parenterally fed bone marrow transplant recipients. JPEN J Parenter Enteral Nutr. 1985 Mar-Apr; 9(2):139-43. PMID: 3921730.
      Citations: 6     Fields:    Translation:Humans
    124. Szeluga DJ, Stuart RK, Utermohlen V, Santos GW, Szeluga DJ, Stuart RK, Utermohlen V, Santos GW. Nutritional assessment by isotope dilution analysis of body composition. Am J Clin Nutr. 1984 Oct; 40(4):847-54. PMID: 6385688.
      Citations: 3     Fields:    Translation:HumansCells
    125. Camitta B, O'Reilly RJ, Sensenbrenner L, Rappeport J, Champlin R, Doney K, August C, Hoffmann RG, Kirkpatrick D, Stuart R, Santos G, Parkman R, Gale RP, Storb R, Nathan D, Camitta B, O'Reilly RJ, Sensenbrenner L, Rappeport J, Champlin R, Doney K, August C, Hoffmann RG, Kirkpatrick D, Stuart R, Santos G, Parkman R, Gale RP, Storb R, Nathan D. Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia. Blood. 1983 Oct; 62(4):883-8. PMID: 6349719.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    126. Strauss LC, Stuart RK, Civin CI, Strauss LC, Stuart RK, Civin CI. Antigenic analysis of hematopoiesis. I. Expression of the My-1 granulocyte surface antigen on human marrow cells and leukemic cell lines. Blood. 1983 Jun; 61(6):1222-31. PMID: 6839022.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    127. Kaizer H, Tutschka P, Stuart R, Korbling M, Braine H, Saral R, Colvin M, Santos G, Kaizer H, Tutschka P, Stuart R, Korbling M, Braine H, Saral R, Colvin M, Santos G. Autologous bone marrow transplantation in acute leukemia and non-Hodgkin's lymphoma: a phase I study of 4-hydroperoxycyclophosphamide (4HC) incubation of marrow prior to cryopreservation. Haematol Blood Transfus. 1983; 28:90-1. PMID: 6345299.
      Citations:    Fields:    Translation:HumansCells
    128. Braine HG, Stuart RK, Saral R, Lietman PS, Braine HG, Stuart RK, Saral R, Lietman PS. Parenteral trimethoprim-sulfamethoxazole and carbenicillin as empiric therapy for neutropenic patients with cancer. Rev Infect Dis. 1982 Mar-Apr; 4(2):586-92. PMID: 7051248.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    129. Sieber F, Stuart RK, Spivak JL, Sieber F, Stuart RK, Spivak JL. Tumor-promoting phorbol esters stimulate myelopoiesis and suppress erythropoiesis in cultures of mouse bone marrow cells. Proc Natl Acad Sci U S A. 1981 Jul; 78(7):4402-6. PMID: 6945590; PMCID: PMC319798.
      Citations: 5     Fields:    Translation:AnimalsCells
    130. Stuart RK, Hamilton JA, Sensenbrenner LL, Moore MA, Stuart RK, Hamilton JA, Sensenbrenner LL, Moore MA. Regulation of myelopoiesis in vitro: partial replacement of colony-stimulating factors by tumor-promoting phorbol esters. Blood. 1981 Jun; 57(6):1032-42. PMID: 6971664.
      Citations: 4     Fields:    Translation:AnimalsCells
    131. Orr RK, Hoehn JL, Col NF, Spivak JL, Misiti J, Stuart R, Sharkis SJ, Sensenbrenner LL. Suppression and potentiation of mouse hematopoietic progenitor cell proliferation by ouabain. Blood. 1980 Aug; 56(2):315-7. PMID: 7397383.
      Citations: 2     Fields:    Translation:AnimalsCells
    132. Stuart RK, Braine HG, Lietman PS, Saral R, Fuller DJ, Stuart RK, Braine HG, Lietman PS, Saral R, Fuller DJ. Carbenicillin-trimethoprim/sulfamethoxazole versus carbenicillin-gentamicin as empiric therapy of infection in granulocytopenic patients. A prospective, randomized, double-blind study. Am J Med. 1980 Jun; 68(6):876-85. PMID: 6992570.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    133. Stuart RK, Hamilton JA, Stuart RK, Hamilton JA. Tumor-promoting phorbol esters stimulate hematopoietic colony formation in vitro. Science. 1980 Apr 25; 208(4442):402-4. PMID: 6245446.
      Citations: 12     Fields:    Translation:AnimalsCells
    134. Sharkis SJ, Spivak JL, Ahmed A, Misiti J, Stuart RK, Wiktor-Jedrzejczak W, Sell KW, Sensenbrenner LL, Sharkis SJ, Spivak JL, Ahmed A, Misiti J, Stuart RK, Wiktor-Jedrzejczak W, Sell KW, Sensenbrenner LL. Regulation of hematopoiesis: helper and suppressor influences of the thymus. Blood. 1980 Mar; 55(3):524-7. PMID: 6153538.
      Citations: 2     Fields:    Translation:AnimalsCells
    135. Stuart RK, Stuart RK. A new design for randomized trials. N Engl J Med. 1979 Oct 04; 301(14):786. PMID: 481493.
      Citations:    Fields:    Translation:Humans
    136. Stuart RK, Sensenbrenner LL, Stuart RK, Sensenbrenner LL. Adverse effects of nutritional deprivation on transplanted hematopoietic cells. Exp Hematol. 1979 Sep; 7(8):435-42. PMID: 389654.
      Citations:    Fields:    Translation:Animals
    137. Thomas DP, Ream VJ, Stuart RK, Thomas DP, Ream VJ, Stuart RK. Platelet aggregation in patients with Laennec's cirrhosis of the liver. N Engl J Med. 1967 Jun 15; 276(24):1344-8. PMID: 6024565.
      Citations: 12     Fields:    Translation:HumansCells
    Stuart's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (609)
    Explore
    _
    Co-Authors (41)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _